Singletine - Guangzhou JOYO Pharma
Alternative Names: DC-407Latest Information Update: 23 Sep 2025
At a glance
- Originator Guangzhou JOYO Pharma
- Developer Guangzhou JOYO Pharma; Shanghai Institute of Materia Medica
- Class Antihyperglycaemics; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Diabetes mellitus; Fatty liver
Most Recent Events
- 03 Jun 2025 Guangzhou JOYO Pharma completes phase-I/II clinical trials in Diabetes mellitus and Fatty liver in China (PO) (CTR20221874)
- 30 Aug 2022 Phase-I/II clinical trials in Diabetes mellitus in China (PO) (CTR20221874)
- 30 Aug 2022 Phase-I/II clinical trials in Fatty liver in China (PO) (CTR20221874)